This report provides an environmental analysis of the current precision medicine and genomics market in the United States healthcare industry. According to the National Institutes of Health (NIH), precision medicine is “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.”1 Precision medicine goes hand in hand with “genomics” research. Genomic information can be utilized to help diagnose and treat a person’s disease. In the last several years, many provider organizations have launched new initiatives in precision medicine and genomics in an effort to improve patient outcomes. To better understand the current state of the market, the Foundation for eHealth Initiative conducted a series of interviews with executives at leading provider organizations across the country. The adopters ranged from early adopters of precision medicine who have been in this space for up to fifteen years, to those who are just starting to develop their genomics research arm. The Foundation for eHealth Initiative (eHI) is a neutral, non-profit organization which convenes executives from multi-stakeholder groups to identify best practices to transform care through use of information and innovation. As such, eHI spearheaded an effort to interview and assess the state of the field. The findings shared in this report provide insight on how clinical and genetic data is used and managed, as well as the challenges providers face in genomics research and precision medicine. 

White paper by Oracle on how technology can support evidence-based medicine and improve the value of care.

An update to the 2008 guide to e-Prescribing.

eHI recently interviewed a number of leading healthcare organizations to learn about their data management strategies